Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Panel of Genetic Variations as a Potential Non-invasive Biomarker for Early Diagnosis of Alzheimer's Disease.

Ma SL, Lam LC.

Clin Psychopharmacol Neurosci. 2011 Aug;9(2):54-66. doi: 10.9758/cpn.2011.9.2.54. Epub 2011 Aug 31.

2.

Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis.

Struyfs H, Van Broeck B, Timmers M, Fransen E, Sleegers K, Van Broeckhoven C, De Deyn PP, Streffer JR, Mercken M, Engelborghs S.

J Alzheimers Dis. 2015;45(3):813-22. doi: 10.3233/JAD-141986.

PMID:
25633670
3.

An Integrated Bioinformatics Approach for Identifying Genetic Markers that Predict Cerebrospinal Fluid Biomarker p-tau181/Aβ1-42 Ratio in ApoE4-Negative Mild Cognitive Impairment Patients.

Sun Y, Bresell A, Rantalainen M, Höglund K, Lebouvier T, Salter H; Alzheimer Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;45(4):1061-76. doi: 10.3233/JAD-142118.

PMID:
25720397
4.

Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.

Elias-Sonnenschein LS, Helisalmi S, Natunen T, Hall A, Paajanen T, Herukka SK, Laitinen M, Remes AM, Koivisto AM, Mattila KM, Lehtimäki T, Verhey FR, Visser PJ, Soininen H, Hiltunen M.

PLoS One. 2013;8(4):e59676. doi: 10.1371/journal.pone.0059676. Epub 2013 Apr 3.

5.

Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Ritchie C, Smailagic N, Noel-Storr AH, Takwoingi Y, Flicker L, Mason SE, McShane R.

Cochrane Database Syst Rev. 2014 Jun 10;(6):CD008782. doi: 10.1002/14651858.CD008782.pub4. Review.

PMID:
24913723
6.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
7.

Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.

Han MR, Schellenberg GD, Wang LS; Alzheimer's Disease Neuroimaging Initiative.

BMC Neurol. 2010 Oct 8;10:90. doi: 10.1186/1471-2377-10-90.

8.

ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.

Apostolova LG, Hwang KS, Kohannim O, Avila D, Elashoff D, Jack CR Jr, Shaw L, Trojanowski JQ, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2014 Jan 4;4:461-72. doi: 10.1016/j.nicl.2013.12.012. eCollection 2014.

9.

Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.

Li QX, Villemagne VL, Doecke JD, Rembach A, Sarros S, Varghese S, McGlade A, Laughton KM, Pertile KK, Fowler CJ, Rumble RL, Trounson BO, Taddei K, Rainey-Smith SR, Laws SM, Robertson JS, Evered LA, Silbert B, Ellis KA, Rowe CC, Macaulay SL, Darby D, Martins RN, Ames D, Masters CL, Collins S; AIBL Research Group.

J Alzheimers Dis. 2015;48(1):175-87. doi: 10.3233/JAD-150247.

PMID:
26401938
10.

Genetics of Alzheimer's disease.

Chouraki V, Seshadri S.

Adv Genet. 2014;87:245-94. doi: 10.1016/B978-0-12-800149-3.00005-6. Review.

PMID:
25311924
11.

Effects of Alzheimer's disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: a polygenic risk score approach.

Martiskainen H, Helisalmi S, Viswanathan J, Kurki M, Hall A, Herukka SK, Sarajärvi T, Natunen T, Kurkinen KM, Huovinen J, Mäkinen P, Laitinen M, Koivisto AM, Mattila KM, Lehtimäki T, Remes AM, Leinonen V, Haapasalo A, Soininen H, Hiltunen M.

J Alzheimers Dis. 2015;43(2):565-73. doi: 10.3233/JAD-140777.

PMID:
25096612
12.

Plasma beta-amyloid as potential biomarker of Alzheimer disease: possibility of diagnostic tool for Alzheimer disease.

Takeda S, Sato N, Rakugi H, Morishita R.

Mol Biosyst. 2010 Oct;6(10):1760-6. doi: 10.1039/c003148h. Epub 2010 Jun 21. Review.

PMID:
20567751
13.

Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.

Susanto TA, Pua EP, Zhou J; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;45(1):253-68. doi: 10.3233/JAD-142451.

PMID:
25524955
14.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
15.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
16.

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.

Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.

Methods. 2012 Apr;56(4):484-93. doi: 10.1016/j.ymeth.2012.03.023. Epub 2012 Apr 6. Review.

PMID:
22503777
17.

Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting.

Malnar M, Kosicek M, Bene R, Tarnik IP, Pavelin S, Babic I, Brajenovic-Milic B, Hecimovic H, Titlic M, Trkanjec Z, Demarin I, Hecimovic S.

Acta Neurobiol Exp (Wars). 2012;72(3):264-71.

18.

Impact of SORL1 single nucleotide polymorphisms on Alzheimer's disease cerebrospinal fluid markers.

Alexopoulos P, Guo LH, Kratzer M, Westerteicher C, Kurz A, Perneczky R.

Dement Geriatr Cogn Disord. 2011;32(3):164-70. doi: 10.1159/000332017. Epub 2011 Oct 13.

19.

Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.

Weise D, Tiepolt S, Awissus C, Hoffmann KT, Lobsien D, Kaiser T, Barthel H, Sabri O, Gertz HJ.

J Alzheimers Dis. 2015;48(2):425-32. doi: 10.3233/JAD-150229.

PMID:
26402006
20.

[The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].

Croisile B, Auriacombe S, Etcharry-Bouyx F, Vercelletto M; National Institute on Aging (u.s.); Alzheimer Association.

Rev Neurol (Paris). 2012 Jun;168(6-7):471-82. doi: 10.1016/j.neurol.2011.11.007. Epub 2012 May 12. Review. French.

PMID:
22579080

Supplemental Content

Support Center